NCT03653507 2026-04-17
GLOW
Astellas Pharma Inc
Phase 3 Active not recruiting
Clinical Trials
15 trialsNCT05152147 2026-04-17
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
NCT05568095 2026-04-02
STAR-221
Arcus Biosciences, Inc.
Phase 3 Active not recruiting
NCT05052801 2026-02-19
FORTITUDE-101
Amgen
Phase 3 Active not recruiting
NCT03504397 2026-02-13
Spotlight
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT03399110 2026-01-27
XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)
Fudan University
Phase 3 Active not recruiting
NCT04704934 2026-01-12
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Daiichi Sankyo
Phase 3 Active not recruiting
NCT05111626 2025-12-15
FORTITUDE-102
Amgen
Phase 3 Active not recruiting
NCT03348150 2025-07-17
PERISCOPEII
The Netherlands Cancer Institute
Phase 3 Active not recruiting
NCT06939439 2025-07-01
Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Active not recruiting
NCT02112214 2024-12-27
HELPER
National Cancer Center, Korea
Phase 3 Active not recruiting
NCT05144854 2024-09-05
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Ono Pharmaceutical Co. Ltd
Phase 3 Active not recruiting
NCT01678027 2023-11-09
Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication
National Cancer Center, Korea
Phase 3 Active not recruiting
NCT02407119 2023-11-09
Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD
National Cancer Center, Korea
Phase 3 Active not recruiting
NCT04611997 2023-09-18
IGG Using in Laparoscopic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
Fujian Medical University
Phase 3 Active not recruiting